B precursor type acute leukaemia – Diagnostics – Overview of Information and Clinical Research

B precursor type acute leukaemia, also known as precursor B-cell acute lymphoblastic leukaemia or B-ALL, is a fast-growing blood cancer that affects immature white blood cells in the bone marrow. Early and accurate diagnosis is essential for starting treatment quickly and improving the chances of successful outcomes, particularly since this disease can progress rapidly over days or weeks.

Introduction: Who Should Undergo Diagnostics

People who should seek diagnostic testing for B precursor type acute leukaemia are those experiencing persistent warning signs that don’t improve with time. Unlike common illnesses such as the flu, which typically get better after a few days, the symptoms of this blood cancer continue or worsen without treatment. It’s important to understand that many early signs of B-ALL can mimic other less serious conditions, which is why medical evaluation becomes crucial when symptoms persist.^[1]

Anyone experiencing ongoing fatigue that doesn’t improve with rest, frequent infections that seem to occur one after another, or unusual bleeding and bruising should consider speaking with their doctor. These symptoms happen because the bone marrow, which normally produces healthy blood cells, starts making too many abnormal, immature B-cells called lymphoblasts. These abnormal cells crowd out the healthy cells, leaving the body without enough properly functioning blood components to maintain normal health.^[2]

Children and young adults are particularly at risk for this type of leukaemia. B-ALL is the most common type of childhood leukaemia, with around 75% of all B-ALL cases affecting children younger than six years old. However, adults can develop this condition too, and it’s important to note that around 75% of adults diagnosed with acute lymphoblastic leukaemia have the B-ALL subtype specifically. Anyone with a family history of leukaemia, especially siblings of affected individuals, should be particularly vigilant about symptoms.^[2]

Certain groups of people face higher risk and may need more careful monitoring. Children with genetic conditions such as Down syndrome have an increased chance of developing B-ALL. Those who have previously been exposed to high levels of radiation, X-rays, or chemotherapy treatments for other conditions also carry elevated risk. Additionally, people with suppressed immune systems, usually from medications taken after organ transplantation, should be aware of their increased vulnerability to this disease.^[2]

Diagnostic testing should be pursued urgently if someone experiences a combination of concerning symptoms. These include unintended weight loss or decreased appetite, difficulty breathing, easy bruising or excessive bleeding from the gums or nose, bone or joint pain, abdominal pain from an enlarged liver or spleen, recurrent fevers, swollen lymph nodes in the neck, armpit, or groin, or frequent infections that don’t resolve normally. The presence of multiple symptoms together is especially concerning and warrants immediate medical attention.^[2]^[8]

⚠️ Important

Because B precursor type acute leukaemia develops quickly over days or weeks, people with this condition usually need to start treatment soon after being diagnosed. Delaying medical evaluation when symptoms are present could allow the disease to progress and spread to other parts of the body, including the lymph nodes, liver, spleen, brain, spinal cord, and in rare cases, the testicles. Early diagnosis gives the best chance for successful treatment.

Diagnostic Methods Used to Identify the Disease

The diagnostic process for B precursor type acute leukaemia begins with a thorough physical examination and a detailed discussion about medical history. During the physical exam, doctors look for signs such as swollen lymph nodes, an enlarged liver or spleen, and other physical indicators that might suggest leukaemia. They will ask about symptoms, how long they have been present, and whether there are any risk factors such as previous radiation exposure or genetic conditions in the family.^[2]

Blood tests are typically the first laboratory step in diagnosing B-ALL. These tests count the number of different types of blood cells in a sample, including platelets (which help blood clot), white blood cells (which fight infection), and red blood cells (which carry oxygen throughout the body). In someone with B precursor type acute leukaemia, these counts are often abnormal. There may be too many immature white blood cells called blast cells, and too few healthy red blood cells and platelets. Blood tests also evaluate liver and kidney function and can detect signs of inflammation and infection that might accompany the disease.^[2]

The most reliable and common method for confirming a diagnosis of B-ALL is bone marrow aspiration or biopsy. This procedure involves using a thin, hollow needle to remove small samples of bone marrow tissue or actual bone for detailed analysis. The bone marrow is examined under a microscope to look for the presence of abnormal lymphoblasts and to determine what percentage of cells in the marrow are cancerous. This test is considered the gold standard for diagnosing B precursor type acute leukaemia because it provides direct evidence of what is happening where blood cells are made.^[2]

Once leukaemia cells are identified, additional specialized tests are performed on the bone marrow or blood samples to understand exactly what type of leukaemia is present. These include tests that look at the surface markers on the leukaemia cells. Precursor B-cell ALL cells typically express specific proteins on their surface, including CD10, CD19, and CD34, along with a marker inside the cell nucleus called terminal deoxynucleotide transferase, or TdT. Identifying these markers helps doctors distinguish B-ALL from other types of leukaemia, particularly T-cell acute lymphoblastic leukaemia, which has different surface markers.^[12]^[14]

Genetic and molecular testing of the leukaemia cells provides crucial information about the specific subtype of B-ALL and helps predict how the disease might respond to treatment. Some patients have a genetic abnormality called the Philadelphia chromosome, which occurs when a gene called ABL1 on chromosome 9 breaks off and attaches to a gene called BCR on chromosome 22. This creates a new fusion gene called BCR-ABL1 that causes cells to produce too much of a protein that encourages leukaemia cells to grow. This Philadelphia positive subtype affects about 20 to 30% of adults with ALL and is more common in older people. Detecting this abnormality is important because these patients can be treated with targeted drugs.^[1]^[12]

Many patients who have the BCR-ABL1 fusion gene don’t show the abnormal chromosome through standard genetic testing. In these cases, more sensitive techniques such as fluorescence in situ hybridization (FISH) or reverse transcription-polymerase chain reaction (RT-PCR) must be used. These molecular tests can detect the genetic abnormality even when it’s not visible through traditional chromosome analysis. Doctors should perform these tests whenever possible in patients with ALL, especially those with B-cell lineage disease, because identifying this mutation significantly affects treatment choices.^[12]

Other genetic abnormalities are also looked for during diagnosis. Some people have translocations involving different chromosomes, such as t(12;21), which involves the ETV and CBFα genes. This particular translocation is associated with a better outlook compared to other genetic changes. More than 200 different fusion genes or mutated genes have been identified in ALL patients, and about two-thirds of pediatric B-ALL patients have specific chromosomal translocations that play crucial roles in determining risk and guiding treatment strategy.^[4]^[6]

Imaging tests help determine the extent of the disease and whether it has spread to other parts of the body. These tests also help locate enlarged lymph nodes and organs such as the liver or spleen. Chest X-rays are commonly performed to check for enlarged lymph nodes in the chest or fluid accumulation. Computed tomography (CT) scans provide more detailed cross-sectional images of the body and can identify tumors or enlarged organs. Magnetic resonance imaging (MRI) scans use magnets and radio waves instead of radiation and are particularly useful for examining the brain and spinal cord. Ultrasound imaging uses sound waves and is helpful for assessing abdominal organs. In some cases, doctors may order positron emission tomography (PET) scans or echocardiograms to evaluate heart function before starting certain treatments.^[2]^[11]

A lumbar puncture, also called a spinal tap, may be performed to determine whether leukaemia has spread to the brain or spinal cord. During this procedure, a thin needle is inserted between bones in the lower spine to collect a sample of cerebrospinal fluid, the liquid that surrounds the brain and spinal cord. This fluid is examined under a microscope for the presence of leukaemia cells. Because B-ALL can spread to the central nervous system, checking the cerebrospinal fluid is an important part of the complete diagnostic evaluation.^[2]^[11]

Diagnostics for Clinical Trial Qualification

When patients are being considered for enrollment in clinical trials studying new treatments for B precursor type acute leukaemia, they must undergo additional diagnostic evaluations beyond those used for standard diagnosis. Clinical trials have specific eligibility criteria to ensure patient safety and to obtain reliable scientific results. Understanding whether a patient meets these criteria requires precise diagnostic testing performed according to strict protocols.

One of the most important diagnostic criteria for clinical trial enrollment is the confirmation of disease subtype through detailed cellular and molecular characterization. Trials for B-ALL specifically require proof that the leukaemia affects B-cell precursors rather than T-cells or other cell types. This is established through immunophenotyping, which identifies the specific surface markers and internal proteins expressed by the leukaemia cells. The presence of markers such as CD10, CD19, and CD34, combined with TdT, confirms the B-cell precursor lineage and makes a patient eligible for B-ALL-specific trials.^[12]^[14]

Genetic testing to identify specific chromosomal abnormalities is essential for many clinical trials. Some trials specifically enroll patients with Philadelphia chromosome-positive disease, while others focus on patients who are Philadelphia chromosome-negative. Comprehensive genetic testing using techniques such as FISH, RT-PCR, or next-generation sequencing must be completed to determine eligibility. The results must be documented before enrollment to ensure patients receive treatments appropriate for their genetic subtype.^[12]

Assessment of disease burden at the time of potential trial enrollment is another critical diagnostic requirement. Most clinical trials measure disease burden through bone marrow examination to determine the percentage of blast cells present. For trials involving newly diagnosed patients, doctors typically require confirmation that at least 20% of bone marrow cells are leukaemia blasts. For trials studying relapsed or refractory disease, different thresholds may apply. Blood counts must also be documented, including white blood cell count, hemoglobin level, and platelet count, as these factors often determine trial eligibility and risk stratification.^[6]

Evaluation of measurable residual disease (MRD) has become increasingly important in clinical trials for B-ALL. MRD refers to small numbers of leukaemia cells that remain in the body after treatment but are too few to detect through standard microscopic examination. Advanced molecular techniques can detect as few as one leukaemia cell among 10,000 or even 100,000 normal cells. Many clinical trials now use MRD status as an eligibility criterion, an outcome measure, or both. Patients may need to have MRD testing performed at specific time points, such as after induction therapy, to determine whether they remain eligible for certain trial phases.^[6]

Organ function testing is required before entering most clinical trials to ensure patients can safely tolerate the experimental treatments being studied. Blood tests measuring kidney function, including creatinine and blood urea nitrogen levels, help determine whether kidneys are working well enough to process chemotherapy drugs. Liver function tests, which measure enzymes and proteins produced by the liver, indicate whether the liver can metabolize medications properly. Heart function must also be assessed, typically through echocardiograms or other cardiac imaging, especially for trials involving drugs that might affect the heart. These baseline measurements establish a starting point for monitoring potential side effects during the trial.^[2]

Testing for infectious diseases is commonly required before clinical trial enrollment. Patients typically undergo blood tests for viruses such as hepatitis B, hepatitis C, and HIV, as these infections can affect treatment safety and efficacy. Some trials may also require testing for other infections depending on the treatments being studied and the patient’s risk factors. Active infections may delay trial enrollment until they are treated and resolved.

Age and performance status are documented as part of the diagnostic evaluation for trial eligibility. While age can be determined simply from birth records, performance status requires clinical assessment using standardized scales. These scales measure how well a person can perform daily activities and care for themselves. Clinical trials often specify that patients must have a certain minimum performance status to be eligible, as this helps predict their ability to tolerate intensive treatments.

For trials studying treatments aimed at preventing or treating central nervous system involvement, lumbar puncture with cerebrospinal fluid analysis is typically required. This establishes whether leukaemia cells are present in the fluid surrounding the brain and spinal cord at the start of the trial. The results determine whether patients are eligible for specific trial arms and influence the choice of preventive or therapeutic interventions for central nervous system disease.

Baseline quality of life assessments and symptom inventories are increasingly included in clinical trial diagnostic protocols. While these aren’t medical tests in the traditional sense, they are systematic evaluations that document the patient’s physical, emotional, and social well-being before treatment begins. These baseline measurements allow researchers to assess whether new treatments improve or worsen quality of life compared to standard therapies.

⚠️ Important

Clinical trials often have very specific diagnostic requirements that go beyond what is needed for standard diagnosis and treatment. Patients interested in participating in clinical trials should discuss testing requirements with their care team early in the diagnostic process. Some specialized tests may take several days or weeks to complete, and understanding these requirements upfront can prevent delays in trial enrollment if a patient is found to be eligible.

Prognosis and Survival Rate

Prognosis

The outlook for people with B precursor type acute leukaemia depends on several important factors that doctors consider when predicting how the disease might progress. Age is one of the most significant factors affecting prognosis. Children with B-ALL generally have much better outcomes than adults. The disease is highly treatable in young patients, with modern treatment approaches resulting in very good chances for long-term survival. However, as people get older, the prognosis becomes less favorable, and adults, particularly those over age 50, face more challenging outlooks.^[9]

The genetic characteristics of the leukaemia cells play a crucial role in determining prognosis. Certain chromosomal abnormalities indicate better or worse outcomes. For example, the translocation t(12;21) involving the ETV and CBFα genes is associated with a better prognosis compared to other genetic changes. Conversely, some genetic abnormalities suggest the disease may be more aggressive or harder to treat. The presence or absence of the Philadelphia chromosome also significantly influences prognosis, as this determines whether targeted therapies can be used as part of the treatment plan.^[4]^[6]

Early response to treatment is one of the most important predictors of long-term outcome. Patients who achieve rapid and deep reduction in disease burden, particularly those who become negative for measurable residual disease early in treatment, tend to have better prognoses. The speed at which leukaemia cells disappear from the bone marrow and blood after starting therapy helps doctors understand how sensitive the disease is to treatment. This information is used for risk stratification, which means categorizing patients into different risk groups that receive appropriately intensive treatment protocols.^[6]

The initial white blood cell count at diagnosis provides prognostic information. Higher counts at the time of diagnosis generally indicate more aggressive disease and are associated with increased risk of complications. Other factors that influence prognosis include whether the disease has spread to the central nervous system, the overall health and fitness level of the patient, and whether any organ dysfunction is present when treatment begins.

For adults with B precursor type acute leukaemia, treatment can work well for some people, but survival depends on many factors including those mentioned above. The prognosis remains particularly difficult for adults and children whose disease relapses after initial treatment. Relapsed B-ALL continues to be the leading cause of cancer-related death in children and young adults, highlighting the importance of achieving the best possible response with initial treatment.^[1]^[6]

Survival rate

Survival statistics for B precursor type acute leukaemia show a stark difference between children and adults. For children with B-ALL, modern treatment protocols have achieved remarkable success. Around 85% of children with B-ALL remain cancer-free five years after diagnosis. The five-year survival rate for pediatric B-ALL is above 90%, making it one of the most curable childhood cancers. These excellent outcomes reflect decades of research and refinement of treatment approaches specifically designed for young patients.^[2]

The statistics are less encouraging for adults. Among adults with B-ALL, the five-year survival rate is around 40% for those over age 20. This significant difference between pediatric and adult outcomes reflects several factors, including differences in disease biology, the ability to tolerate intensive chemotherapy, and the presence of more high-risk genetic features in adult cases. Young adults aged between 15 and 39 have outcomes that fall somewhere between childhood and older adult results, with approximately 65% surviving five years or more after diagnosis when treated with appropriate protocols.^[2]

For all people with acute lymphoblastic leukaemia in England, where detailed statistics are available, around 85% survive for one year or more after diagnosis, and 70% survive for five years or more. These figures represent all types of ALL combined and all age groups. Younger people within this overall group tend to have better survival rates than these averages, while older individuals face more difficult odds.^[22]

It’s important to understand that survival statistics are based on large groups of patients diagnosed and treated in previous years. Individual outcomes can vary significantly based on specific characteristics of the disease, the patient’s overall health, and advances in treatment that may have occurred since the statistics were compiled. Newer therapies and treatment approaches continue to improve outcomes, particularly for certain subgroups of patients. The statistics provide general guidance about what to expect but cannot predict exactly what will happen for any individual person.

The concept of “cure” in B-ALL means achieving long-term remission where the disease does not return. For children, B-ALL has become the most curable malignancy, with long-term survival rates approaching 90% in newly diagnosed patients. However, relapse remains a significant concern. When the disease comes back after initial treatment, the prognosis becomes much more difficult, and these patients represent a major focus of ongoing research efforts to develop more effective therapies.^[6]

#1 Clinical Trials Search in Europe